Background: Increased C-reactive protein (CRP) is a known predictor of vascular events in asymptomatic individuals and stroke patients. Only a few studies included transient ischaemic attack (TIA) patients. We assessed CRP levels in addition to traditional risk factors in a cohort of patients with TIA to examine the relationship of these parameters to the occurrence of ischaemic stroke. Methods: This is a prospective, longitudinal clinical evaluation of the efficacy of CRP as a prognostic indicator. CRP levels were measured in 194 TIA patients and in 1,024 asymptomatic individuals (recruited from a project on stroke prevention, the PrATO, which was ongoing at the same time in the Aosta Valley). A clinical risk score was determined using the ABCD2 score in TIA patients. The area under the receiver operating characteristic curve (AUC) was used to evaluate the significance of the markers as predictors. Two models were evaluated: model 1 used the ABCD2 score and model 2 used serum CRP levels in addition to the ABCD2 score. The primary outcome was an ischaemic stroke. Results: Within 2 years ischaemic strokes occurred in 33/194 patients. The Cox proportional hazards models, after adjustments for conventional risk factors, identified CRP levels ≧3 mg/l and ABCD2 scores ≧4 as independent predictors of stroke. The corresponding AUCs were 0.565 and 0.636, based on model 1 and model 2, respectively; this represented a statistically significant difference (p = 0.043). The absolute integrated discrimination improvement was 0.0249 (p = 0.007) and the relative integrated discrimination improvement was 2.3710. The net benefit became significant from a predicted probability ≧10% and was 0.077 when based on model 1 and 0.087 when based on model 2. Conclusions: Routine CRP measurements in the acute phase might be a useful tool for identifying TIA patients who are at a higher risk of ischaemic stroke. The additional use of CRP levels for the risk assessment in TIA patients improves risk definition in terms of the ABCD2 score alone.

1.
Coull AJ, Lovett JK, Rothwell PM: Population based study of early risk of stroke after transient ischemic attack or minor stroke: implication for public education and organisation of services. BMJ 2004;328:326.
2.
Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopflocher DP: The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 2004;62:2015–2020.
3.
Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2009;375:132–140.
4.
Ridker PM, Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004;109:1955–1959.
5.
Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR: C-reactive protein and outcome after ischemic stroke. Stroke 1999;30:981–985.
6.
Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HCA, Forconi S, Hopkins SJ, Masotti L, Muir KW, Paciucci A, Papa F, Roncacci S, Sander D, Smig CJ, Stefanini A, Weber D: Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke. Stroke 2005;36:1316–1329.
7.
Arenillas JF, Alvarez-Sabin J, Molina CA, Chacon P, Montaner J, Rovira A, Ibarra B, Quintana M: C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 2003;34:2463–2470.
8.
Cucchiara LB, Messe SR, Sansing L, MacKenzie L, Taylor RA, Pacelli J, Shah Q, Kasner SE: Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patient with TIA. Stroke 2009;40:2332–2336.
9.
Purroy F, Montaner J, Molina CA, Delgado P, Arenillas JF, Chacon P, Quintana M, Alvares-Sabin J: C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurol Scand 2007;115:60–66.
10.
Rothwell PM, Warlow CP: Timing of transient ischaemic attacks preceding ischaemic stroke. Neurology 2005;64:817–820.
11.
Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S: Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007;369:283–292.
12.
Easton JD, Saver JL, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL: Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. Stroke 2009;40:2276–2293.
13.
NICE Clinical Guideline 68: Stroke: diagnosis and initial management of acute stroke and transient ischaemic attack (TIA). www.nice,org,uk/CG068 (accessed January 2010).
14.
Corso G, Bottacchi E, Giardini G, De la Pierre F, Meloni T, Pesenti Compagnoni M, Ponzetti C, Veronese Morosini M: Community-based study of stroke incidence in the Valley of Aosta, Italy. Neuroepidemiology 2009;32:186–195.
15.
Albers GW, Caplan LR, Easton JD, et al, TIA Working Group: Transient ischaemic attack: proposal for a new definition. N Engl J Med 2002;347:1713–1716.
16.
Hatano S: Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976;54:541–553.
17.
Grant EG, Benson CB, Moneta GI, Alexandrov AV, Baker JD, Bluth EI, Carroll BA, Eliasziw M, Gocke J, Hertzberg BS, Katanick S, Needleman L, Pellerito J, Polak JF, Rholl KS, Wooster DL, Zierler RE: Carotid artery stenosis: gray-scale and Doppler US diagnosis – Society of Radiologists in Ultrasound Consensus Conference. Radiology 2003;229:340–346.
18.
DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–845.
19.
Pencina MJ, D’Agostino RB, D’Agostino RB Jr, Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157–172.
20.
Vickers AJ, Elkin EB: Decision curve analysis: a novel method for evaluating prediction models. Med Decision Making 2006;26:565–574.
21.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease controls and prevention and the American Heart Association. Circulation 2003;107:499–511.
22.
Pasceri V, Cheng JS, Willerson JT, Yet ET, Chang J: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531–2534.
23.
Arenillas JF, Massot A, Sabín J-A, Cadenas I-F, del Rio-Espinola A, Chacon P, Quintana M, Molina CA, Rovina A, Montaner J: C-reactive protein gene C1444T polymorphism and risk of recurrent ischemic events in patients with symptomatic intracranial atherostenoses. Cerebrovasc Dis 2009;28:95–102.
24.
Wu CM, McLaughlink K, Lorenzetti DL, Hill MD, Mamis BJ, Ghali WA: Early risk of stroke after TIA: systemic review and meta-analysis. Arch Intern Med 2007;167:2417–2422.
25.
Merwick A, Albers GW, Amarenco P, Arsava EM, Ay H, Calvet D, Coutts SB, Cucchiara BL, Demchuk AM, Furie KI, Giles MF, Labreuche J, Lavallée PC, Mas JL, Olivot JM, Purroy F, Rotwell PM, Saver JL, Sheehan OC, Stack JP, Walsh C, Kelly PJ: Addition of brain and carotid imaging to the ABCD2 score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol 2010;9:1060–1069.
26.
Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN, Lovelock CE, Binney LE, Bull LM, Cuthbertson FC, Welch SJ, Bosch S, Carasco-Alexander F, Silver LE, Gutnikov SA, Metha Z: Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007;370:1432–1442.
27.
Baigent C, Keech A, Kearney PM, et al: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278.
28.
Amarenco P, Bogousslavsky J, Callahan A, et al: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549–559.
29.
Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, et al: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207.
30.
Kennon S, Price CP, Mills PG, et al: The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001;37:1266–1270.
31.
Di Napoli M, Papa F: Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first ever ischemic stroke. Stroke 2003;34:2922–2929.
32.
Shantikumar S, Grant PJ, Catto AJ, Bamford JM, Carter AM: Elevated C-reactive protein and long-term mortality after ischemic stroke. Relationship with markers of endothelial cell and platelet activation. Stroke 2009;40:977–979.
33.
Okita K, Nishijma H, Murakami T, et al: Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thromb Vasc Biol 2004;24:1868–1873.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.